ABCB1 and cancer: The formulation takes advantage of synergy between PTX and siRNA-MDR1, as the latter downregulated proteins associated with drug resistance (such as P-glycoprotein), thus enhancing efficacy of PTX, a classic cancer drug that prevents microtubule disassembly.